AUS
NZ
UK
CA
USA
IND
Highlight
-Analysts give Abbott Laboratories a "Moderate Buy" rating with a target price of $130.07.
-Recent dividend increase reflects company’s strong financial performance.
-Institutional investors hold 75.18% of Abbott Laboratories' shares.
Abbott Laboratories operates within the NYSE Healthcare stock sector, known for its diverse range of products across pharmaceuticals, diagnostics, and medical devices. With strong institutional backing and consistent growth, the company maintains a positive outlook. Analysts have a "Moderate Buy" consensus, highlighting Abbott’s potential in the healthcare market.
Analysts' Consensus and Performance
Abbott Laboratories (NYSE:ABT) has received a consensus rating of "Moderate Buy" from 16 research firms. Among them, 12 have expressed confidence in its potential, giving it a positive outlook, while four issued a hold recommendation. Analysts have set an average 12-month target price of $130.07, suggesting expectations of steady growth.
The company’s recent quarterly earnings reported $1.21 per share, slightly surpassing analyst estimates. With a year-over-year revenue increase of 4.9% to $10.64 billion, Abbott continues to solidify its presence in the healthcare sector.
Insider and Institutional Activity
Notable insider transactions include the sale of over 141,000 shares by CEO Robert B. Ford, reflecting strategic adjustments in holdings. Despite this activity, institutional investors demonstrate continued confidence. Organizations such as Massachusetts Financial Services Co. and State Street Corp have increased their stakes, contributing to 75.18% ownership of Abbott's shares.
Dividend Growth and Shareholder Returns
Abbott Laboratories recently declared a quarterly dividend of $0.55 per share, reflecting a commitment to rewarding shareholders. The annualized dividend totals $2.20, with a yield of 1.87%, reinforcing its reputation as a stable entity in the healthcare space. This increase aligns with its history of consistent dividend payouts, supported by a payout ratio of 66.87%.
Market Position and Offerings
Abbott operates through four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its broad portfolio addresses critical health concerns, from pharmaceuticals for treating hypertension and migraines to diagnostic tools and nutritional products.
The company’s ability to innovate and diversify has enabled it to maintain a leading position in the global healthcare market. Its focus on addressing a wide range of health needs supports its robust performance and outlook.
Abbott Laboratories stands as a well-established name in the healthcare sector. Analysts' positive ratings, strong institutional ownership, and consistent dividend growth underline its stability. With a broad portfolio catering to diverse health needs, Abbott continues to be a key player in advancing healthcare solutions worldwide.
